CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In this CCR Translations, we discuss the potential for tumor-infiltrating lymphocyte therapy to overcome immune-checkpoint inhibitor resistance through CD4+ mediated and MHCII dependent killing. Validating these results from human tumors has potential to improve the clinical application of adoptive cellular transfer in advanced cancers.

Keyphrases

endothelial cells
cell therapy
nk cells
dendritic cells
stem cells
peripheral blood
induced pluripotent stem cells
young adults
risk assessment